"I would never wade into that because I won't sell anything that I think could lead to harm, and we don't know enough about them." The FDA's own scientists have already recommended against reclassifying these peptides
Solution format at a defined concentration (50 mg/ml) allows researchers to administer precise volumetric doses without requiring on-site weighing and dissolution, reducing a source of dosing variability in protocols requiring repeated or time-sensitive administration
Long-Term Consequences of Repeated Excess Dosing Some patients intentionally run BPC-157 at doses above published protocols, reasoning that more peptide will accelerate healing
Hold the vial horizontally between your palms and roll it back and forth
Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O6-Methylguanine-DNA Methyltransferase Biomarker Analyses
The presented consensus statements, though perhaps not immediately implementable worldwide, can serve as a crucial step toward establishing a roadmap for best practices in health science
